MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting

Core Insights - MiNK Therapeutics, Inc. announced clinical data on agenT-797 for treating severe acute respiratory distress syndrome (ARDS) at the American Thoracic Society Annual Meeting, highlighting its potential in addressing critical unmet needs in immune-compromised patients [1][2]. Company Overview - MiNK Therapeutics is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases, with a scalable manufacturing platform for off-the-shelf delivery [5]. Clinical Findings - A 26-year-old patient with chronic immunosuppression post-renal transplant contracted COVID-19 and developed severe hypoxemic respiratory failure, treated with a single dose of 1x10^9 allogeneic iNKT cells (agenT-797) [8]. - Following treatment, there was a rapid decrease in inflammatory cytokines, and the patient was extubated on day 37, discharged on day 60, and returned to normal activities within 6 months [8].